Dapagliflozin promotes browning of white adipose tissue through the FGFR1-LKB1-AMPK signaling pathway.
Mol Biol Rep
; 51(1): 562, 2024 Apr 21.
Article
in En
| MEDLINE
| ID: mdl-38644407
ABSTRACT
BACKGROUND:
Obesity is associated with a wide variety of metabolic disorders that impose significant burdens on patients and society. The "browning" phenomenon in white adipose tissue (WAT) has emerged as a promising therapeutic strategy to combat metabolic disturbances. However, though the anti-diabetic drug dapagliflozin (DAPA) is thought to promote "browning," the specific mechanism of this was previously unclear.METHODS:
In this study, C57BL/6 J male mice were used to establish an obesity model by high-fat diet feeding, and 3T3-L1 cells were used to induce mature adipocytes and to explore the role and mechanism of DAPA in "browning" through a combination of in vitro and in vivo experiments.RESULTS:
The results show that DAPA promotes WAT "browning" and improves metabolic disorders. Furthermore, we discovered that DAPA activated "browning" through the fibroblast growth factor receptors 1-liver kinase B1-adenosine monophosphate-activated protein kinase signaling pathway.CONCLUSION:
These findings provide a rational basis for the use of DAPA in treating obesity by promoting the browning of white adipose tissue.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzhydryl Compounds
/
Signal Transduction
/
Protein Serine-Threonine Kinases
/
Receptor, Fibroblast Growth Factor, Type 1
/
Adipose Tissue, White
/
Glucosides
Limits:
Animals
Language:
En
Journal:
Mol Biol Rep
Year:
2024
Document type:
Article
Publication country:
HOLANDA
/
HOLLAND
/
NETHERLANDS
/
NL
/
PAISES BAJOS
/
THE NETHERLANDS